IQVIA Holdings Inc. $IQV Shares Bought by Nippon Life Global Investors Americas Inc.

Nippon Life Global Investors Americas Inc. lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 9.3% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 47,350 shares of the medical research company’s stock after purchasing an additional 4,020 shares during the quarter. Nippon Life Global Investors Americas Inc.’s holdings in IQVIA were worth $8,348,000 as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. Sowell Financial Services LLC purchased a new position in IQVIA in the 1st quarter valued at approximately $305,000. Mather Group LLC. increased its holdings in IQVIA by 83.5% during the 1st quarter. Mather Group LLC. now owns 769 shares of the medical research company’s stock worth $136,000 after purchasing an additional 350 shares during the period. Private Advisor Group LLC boosted its stake in shares of IQVIA by 11.6% in the 1st quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company’s stock valued at $958,000 after buying an additional 566 shares during the period. Park Avenue Securities LLC grew its position in shares of IQVIA by 40.4% during the first quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company’s stock worth $956,000 after buying an additional 1,562 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in IQVIA by 34.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company’s stock valued at $2,338,000 after acquiring an additional 3,398 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Down 0.2%

Shares of IQVIA stock opened at $184.24 on Friday. The firm has a market cap of $31.32 billion, a price-to-earnings ratio of 26.66, a price-to-earnings-growth ratio of 2.03 and a beta of 1.32. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $249.54. The company’s 50-day simple moving average is $179.28 and its 200-day simple moving average is $167.65. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.04. The company had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.IQVIA’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the company earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Buying and Selling at IQVIA

In related news, insider Eric Sherbet sold 5,800 shares of the stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares of the company’s stock, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the transaction, the insider owned 2,910 shares of the company’s stock, valued at approximately $557,352.30. The trade was a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on IQV. Truist Financial lifted their price objective on shares of IQVIA from $209.00 to $235.00 and gave the stock a “buy” rating in a research report on Wednesday, July 23rd. Mizuho raised their price target on IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a research note on Friday, July 25th. Barclays lifted their target price on shares of IQVIA from $165.00 to $185.00 and gave the company an “equal weight” rating in a report on Wednesday, July 23rd. Cowen reiterated a “buy” rating on shares of IQVIA in a research note on Wednesday, July 23rd. Finally, Citigroup reissued a “neutral” rating on shares of IQVIA in a research report on Thursday, May 22nd. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $229.86.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.